Lavipharm S.A.(DE:BXA0)
€1.41+0.02 (+2.32%)
DE:BXA0
Lavipharm S.A. financials statements
€1.41
At close:+0.02 (+2.32%)
Lavipharm S.A. (BXA0) Ratios
0 Followers
Lavipharm S.A. Ratios
DE:BXA0's free cash flow for Q2 2026 was €-11.53M. For the 2026 fiscal year, DE:BXA0's free cash flow was decreased by €-12.37M and operating cash flow was €842.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.21 | 1.15 | 1.28 | 1.00 | 1.12 |
| Quick Ratio | 0.68 | 0.62 | 0.86 | 0.76 | 0.70 |
| Cash Ratio | 0.14 | 0.14 | 0.24 | 0.40 | 0.07 |
| Solvency Ratio | 0.15 | 0.19 | 0.08 | 0.03 | 0.05 |
| Operating Cash Flow Ratio | 0.15 | 0.12 | 0.02 | 0.07 | 0.17 |
| Short-Term Operating Cash Flow Coverage | 0.89 | 0.45 | 0.07 | 0.16 | 0.91 |
| Net Current Asset Value | € -21.07M | € -27.71M | € -26.42M | € -28.44M | € -36.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.27 | 0.28 | 0.32 | 0.70 |
| Debt-to-Equity Ratio | 0.50 | 0.64 | 0.76 | 0.92 | -3.74 |
| Debt-to-Capital Ratio | 0.33 | 0.39 | 0.43 | 0.48 | 1.36 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.19 | 0.23 | 0.09 | -0.67 |
| Financial Leverage Ratio | 2.32 | 2.37 | 2.69 | 2.84 | -5.31 |
| Debt Service Coverage Ratio | 1.06 | 1.21 | 0.83 | 0.18 | 0.86 |
| Interest Coverage Ratio | 3.89 | 2.04 | 1.84 | 1.64 | -0.22 |
| Debt to Market Cap | 0.11 | 0.17 | 0.15 | 3.09 | 0.83 |
| Interest Debt Per Share | 0.18 | 0.21 | 0.21 | 1.80 | 2.14 |
| Net Debt to EBITDA | 1.80 | 2.75 | 2.46 | 3.36 | 5.73 |
| Profitability Margins | |||||
| Gross Profit Margin | 46.01% | 44.82% | 45.54% | 41.93% | 36.99% |
| EBIT Margin | 11.44% | 10.75% | 10.83% | 9.98% | 11.53% |
| EBITDA Margin | 19.77% | 19.40% | 19.10% | 14.35% | 15.69% |
| Operating Profit Margin | 11.44% | 8.04% | 8.21% | 6.89% | -1.00% |
| Pretax Profit Margin | 11.99% | 6.81% | 6.38% | 5.78% | 6.92% |
| Net Profit Margin | 9.57% | 16.96% | 3.67% | 2.14% | 4.34% |
| Continuous Operations Profit Margin | 8.07% | 16.36% | 3.87% | 2.43% | 4.35% |
| Net Income Per EBT | 79.83% | 249.22% | 57.62% | 36.95% | 62.72% |
| EBT Per EBIT | 104.79% | 84.66% | 77.66% | 83.90% | -690.20% |
| Return on Assets (ROA) | 4.58% | 7.15% | 1.63% | 0.73% | 3.25% |
| Return on Equity (ROE) | 10.62% | 16.95% | 4.38% | 2.07% | -17.27% |
| Return on Capital Employed (ROCE) | 8.26% | 4.92% | 5.29% | 3.92% | -1.34% |
| Return on Invested Capital (ROIC) | 5.11% | 4.34% | 2.93% | 1.25% | -0.72% |
| Return on Tangible Assets | 7.33% | 11.82% | 2.66% | 1.22% | 3.46% |
| Earnings Yield | 3.65% | 6.71% | 1.40% | 10.09% | 17.45% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.77 | 3.28 | 2.35 | 2.53 | 2.74 |
| Payables Turnover | 3.47 | 3.51 | 2.79 | 2.92 | 3.94 |
| Inventory Turnover | 1.46 | 1.41 | 1.87 | 2.08 | 2.61 |
| Fixed Asset Turnover | 2.85 | 2.48 | 2.61 | 2.29 | 2.38 |
| Asset Turnover | 0.48 | 0.42 | 0.44 | 0.34 | 0.75 |
| Working Capital Turnover Ratio | 8.29 | 6.73 | 10.49 | 30.17 | 10.93 |
| Cash Conversion Cycle | 277.30 | 266.61 | 219.70 | 194.71 | 180.10 |
| Days of Sales Outstanding | 132.01 | 111.25 | 155.50 | 144.19 | 133.03 |
| Days of Inventory Outstanding | 250.61 | 259.32 | 195.21 | 175.51 | 139.80 |
| Days of Payables Outstanding | 105.32 | 103.97 | 131.02 | 124.99 | 92.73 |
| Operating Cycle | 382.62 | 370.57 | 350.71 | 319.70 | 272.83 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.04 | 0.03 | 0.00 | 0.16 | 0.21 |
| Free Cash Flow Per Share | 0.01 | -0.03 | -0.02 | -1.50 | 0.11 |
| Dividend Paid and CapEx Coverage Ratio | 0.84 | 0.50 | 0.13 | 0.09 | 2.00 |
| Capital Expenditure Coverage Ratio | 1.46 | 0.50 | 0.13 | 0.09 | 2.00 |
| Operating Cash Flow Coverage Ratio | 0.24 | 0.14 | 0.02 | 0.09 | 0.10 |
| Operating Cash Flow to Sales Ratio | 0.11 | 0.09 | 0.01 | 0.09 | 0.10 |
| Free Cash Flow Yield | 1.28% | -3.62% | -2.68% | -390.14% | 19.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 27.40 | 14.89 | 71.42 | 9.91 | 5.73 |
| Price-to-Sales (P/S) Ratio | 2.62 | 2.53 | 2.62 | 0.21 | 0.25 |
| Price-to-Book (P/B) Ratio | 2.91 | 2.53 | 3.13 | 0.21 | -0.99 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 78.08 | -27.59 | -37.34 | -0.26 | 5.13 |
| Price-to-Operating Cash Flow Ratio | 24.42 | 27.89 | 247.91 | 2.45 | 2.57 |
| Price-to-Earnings Growth (PEG) Ratio | -0.81 | 0.04 | -1.00 | -0.17 | -0.40 |
| Enterprise Value Multiple | 15.06 | 15.77 | 16.20 | 4.84 | 7.31 |
| Enterprise Value | 186.39M | 162.00M | 157.56M | 27.09M | 45.57M |
| EV to EBITDA | 15.06 | 15.77 | 16.20 | 4.84 | 7.31 |
| EV to Sales | 2.98 | 3.06 | 3.09 | 0.69 | 1.15 |
| EV to Free Cash Flow | 88.67 | -33.42 | -44.02 | -0.84 | 23.68 |
| EV to Operating Cash Flow | 27.73 | 33.78 | 292.32 | 8.04 | 11.86 |
| Tangible Book Value Per Share | 0.04 | 0.02 | -0.01 | -0.27 | -0.71 |
| Shareholders’ Equity Per Share | 0.33 | 0.31 | 0.25 | 1.87 | -0.55 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.33 | -1.40 | 0.39 | 0.58 | 0.37 |
| Revenue Per Share | 0.37 | 0.31 | 0.30 | 1.81 | 2.17 |
| Net Income Per Share | 0.04 | 0.05 | 0.01 | 0.04 | 0.09 |
| Tax Burden | 0.80 | 2.49 | 0.58 | 0.37 | 0.63 |
| Interest Burden | 1.05 | 0.63 | 0.59 | 0.58 | 0.60 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 |
| SG&A to Revenue | 0.18 | 0.18 | 0.05 | 0.06 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.33 | 0.55 | 0.27 | 1.57 | 1.40 |
Currency in EUR
